Lexicon Pharmaceuticals (LXRX) Finished Goods (2023)
Lexicon Pharmaceuticals' (LXRX) quarterly Finished Goods came in at $172000.0 in Q2 2023.
Lexicon Pharmaceuticals (LXRX) Finished Goods (2023) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 1 years of Finished Goods data on file, last reported at $172000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lexicon Pharmaceuticals | 979.13 Mn | 808.47 Mn | 20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 172,000.00 |